Considering that, at present, by the time a clinical diagnosis of PD is made there is already significant alpha-synuclein pathology, an active immunization approach is a particularly exciting prospect, as it may have the ability to protect at-risk groups or even the wider population from alpha-synuclein pathology before the onset of symptoms. The gene discussed is SNCA; the disease is Parkinson disease.